Lab
Rocky Mountain Laboratories LLC
Rocky Mountain Laboratories LLC was paid $2.05M by Medicaid between Aug 2022 and Dec 2024, across 52 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 42% of everything it billed.
33Billing provider infoROCKY MOUNTAIN LABORATORIES LLC
DRAPER, UT 84020
DRAPER, UT 84020
33aNPI1619618469assigned 04/05/2022
33bProvider typeClinical Medical Laboratory
28Total paid$2.05M
24GClaims72,578
24DCodes billed52
24AFirst – last monthAug 2022 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Utah
Rank by total paid#9 of 35
Median peer was paid$385K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 911 | $23K | |
| 2023 | 21,996 | $541K | |
| 2024incomplete | 49,671 | $1.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 42% | 10,090 | 7,957 | $869K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 16% | 7,435 | 6,344 | $318K |
| 87481 | 8.5% | 5,140 | 4,378 | $175K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.0% | 3,666 | 1,949 | $165K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.5% | 3,410 | 1,740 | $133K |
| 87653 | 3.1% | 4,999 | 4,263 | $63K | |
| 87631 | 2.4% | 3,349 | 2,980 | $49K | |
| 87500 | 1.7% | 2,633 | 2,314 | $35K | |
| 87641 | 1.6% | 2,634 | 2,315 | $33K | |
| 87511 | 1.2% | 2,295 | 1,883 | $26K | |
| 87563 | 1.2% | 2,200 | 1,753 | $25K | |
| 87529 | 1.2% | 1,334 | 1,162 | $24K |
40 more codes
| 87640 | 1.2% | 1,688 | $24K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.2% | 2,310 | $24K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 477 | $15K |
| 87505 | <1% | 291 | $15K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,555 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,426 | $13K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,208 | $9K |
| 87506 | <1% | 48 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,230 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 460 | $2K |
| 80061 | Lipid panel | <1% | 796 | $2K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 33 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,095 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 841 | $2K |
| 81003 | <1% | 2,546 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,226 | $1K |
| 80050 | General health panel | <1% | 52 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 552 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 72 | $585.04 |
| 84439 | <1% | 213 | $443.44 | |
| 82607 | <1% | 177 | $333.04 | |
| 80047 | <1% | 117 | $314.72 | |
| 82570 | <1% | 188 | $239.56 | |
| 83735 | <1% | 138 | $218.52 | |
| 82044 | <1% | 193 | $198.57 | |
| 86481 | <1% | 34 | $102.22 | |
| 84481 | <1% | 41 | $96.16 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,737 | $95.19 |
| 82746 | <1% | 28 | $94.39 | |
| 83540 | <1% | 53 | $65.64 | |
| 82728 | <1% | 37 | $65.10 | |
| 84436 | <1% | 60 | $58.86 | |
| 85652 | <1% | 120 | $51.09 | |
| 84550 | <1% | 101 | $30.80 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 30 | $25.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 154 | $4.22 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 30 | $0.00 |
| 87541 | 0% | 12 | $0.00 | |
| 87486 | 0% | 12 | $0.00 | |
| 87581 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTIPIANI, DONNA (BILLING MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Rocky Mountain Laboratories LLC | Aurora, CO | $42K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.